NCT07500818 Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease
| NCT ID | NCT07500818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Interstitial Lung Disease (ILD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-02-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Interstitial lung disease (ILD) often requires histopathological confirmation when high-resolution computed tomography (HRCT) findings are inconclusive. Transbronchial lung cryobiopsy has emerged as a less invasive alternative to surgical lung biopsy, but diagnostic yield remains variable and dependent on biopsy location and procedural precision. Robotic-assisted bronchoscopy (RAB) combined with cone-beam computed tomography (CBCT) may allow more precise navigation to target lung segments and potentially improve biopsy quality and diagnostic yield. This multi-center, investigator-initiated randomized controlled trial will compare conventional bronchoscopy with 2D fluoroscopy guidance versus robotic-assisted bronchoscopy with CBCT guidance for transbronchial lung cryobiopsy in patients undergoing diagnostic evaluation for suspected interstitial lung disease. Participants will be randomized in a 1:1 ratio to undergo either conventional bronchoscopy or robotic-assisted bronchoscopy. In both groups, four cryobiopsies will be obtained from two lung lobes using a 1.7 mm cryoprobe (en-bloc removal for both study arms). The primary endpoint is the rate of definitive histological diagnosis as determined by a blinded multidisciplinary ILD board.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Clinical suspicion of interstitial lung disease requiring histological confirmation * Non-diagnostic HRCT pattern (e.g. probable UIP or indeterminate pattern) * Candidate for transbronchial lung cryobiopsy * Ability to provide informed consent Exclusion Criteria: * Definite UIP pattern on HRCT * Severe pulmonary hypertension * Severe hypoxemia contraindicating bronchoscopy * Coagulopathy or contraindication to biopsy * Pregnancy * Inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07500818 clinical trial?
This trial is open to participants of all sexes, studying Interstitial Lung Disease (ILD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500818 currently recruiting?
Yes, NCT07500818 is actively recruiting participants. Contact the research team at thomas.gaisl@uzh.ch for enrollment information.
Where is the NCT07500818 trial being conducted?
This trial is being conducted at Lucerne, Switzerland, Zurich, Switzerland.
Who is sponsoring the NCT07500818 clinical trial?
NCT07500818 is sponsored by University of Zurich. The trial plans to enroll 30 participants.